Human prostatic acid phosphatase (PAcP) is a prostate epithelium-speci®c dierentiation antigen. The cellular form of PAcP functions as a neutral protein ± tyrosine phosphatase, and is involved in regulating prostate cell growth. Although some information on the PAcP gene structure has been obtained, little is known regarding the cis-and trans-acting factors that regulate its expression. Due to the biological importance of PAcP, we investigated the regulation of its expression. A region upstream of the PAcP gene from 72899 to +87 base pairs was linked to the coding sequence of the chloramphenicol acetyltransferase (CAT) gene. Sequential deletions of the sequence between 72899 and 7205 revealed that, in addition to the basic promoter, the region between 71258 and 7779 represents a positive regulatory element. This 71258/ 7779 fragment could enhance the PAcP promoter activity in PC-3 and DU 145 human prostate cancer cells, but not in non-prostate cancer cells, including WI-38 lung diploid cells, A-431 epidermoid carcinoma cells, and HeLa cervix epitheloid carcinoma cells. Furthermore, this ciselement together with the promoter sequence could drive a high level of expression of green¯uorescent protein (GFP) in PC-3 cells, but not in HeLa cells. The prostate-speci®c expression was further examined by injecting naked plasmid DNA into the prostate and the hamstring muscle of mice. The¯uorescence pattern clearly showed that the level of GFP expression is consistently higher in prostate cells than in muscle cells of the intact animal. The data collectively indicate that region between 71258 and 7779 is involved in governing the cell type-speci®c expression of the PAcP gene.
Introduction
The molecular events that lead to the initiation of transcription by RNA polymerase II in eukaryotes have been intensively investigated in recent years. The transcription process is controlled by the promoter and enhancer elements, both of which have a modular structure. The architecture of promoter and enhancer elements re¯ects the combinatorial control of gene expression by dierent transcriptional factors. Each gene is under the control of a multiplicity of elements, sometimes redundant, that can be dispersed over several kilobase (kb) around or within a gene.
A striking aspect of gene regulation in higher eukaryotes is the tissue-restricted expression nature of several genes. This can be controlled by transcription factors, which are themselves expressed in a limited number of cell types. An example of this phenomenon is the liver-speci®c gene transcription in vertebrates (Culig et al., 1993) . Analyses of hepatocyte-speci®c promoters and enhancers have converged towards the characterization of a limited number of DNA-binding transcription factors. Contrary to initial expectations, none of these factors has strict liver-speci®c expression, although each of them is expressed only in a limited number of other cell types. Apparently each cell type expresses a unique combination of restricted factors, which can cooperate with ubiquitous transcription factors in regulating cell type-speci®c expression. Further investigations are important to reveal the molecular mechanism of this mode of regulation.
Several genes whose expression is restricted to prostate cells have been identi®ed. These genes include probasin, a rat dorsolateral prostate protein, rat prostatic steroid-binding protein (PSBP C3(1)), and human prostate-speci®c antigen (PSA), as well as prostatic acid phosphatase (PAcP) genes. Studies with transgenic mice show that certain regions of the probasin and the PSBP C3(1) genes can confer prostate speci®city (Allison et al., 1989; Greenberg et al., 1994) . Nevertheless, when a 5-kb DNA fragment upstream of the rat PSBP C3(1) gene is used to drive the expression of the SV40 T-antigen, the gene expression is not restricted and other abnormalities are common, even though tumors are elicited only in the prostate (Maroulakou et al., 1994) . Although some factors that bind to regions of the PSBP C3(1) gene promoter and its ®rst intron have been identi®ed (Murtha et al., 1993) , genetic elements that confer the prostate-speci®c expression remain to be further characterized. Similarly, the tissue-speci®c expression driven by the probasin promoter has a limited success rate (Brookes et al., 1998) . When a 630-bp PSA promoter DNA is used, the expression of an activated Ha-ras oncogene in transgenic mice leads to the development of salivary gland tumors, but not prostate tumors (Schaner et al., 1995) . An androgen-responsive prostate-speci®c enhancer which may be responsible for the speci®c expression of human PSA gene has been located between 75824 and 73738 bp (Schuur et al., 1996) . Nevertheless, further studies of the prostate-speci®c expression are needed, due to the potential applications in prostate cancer therapy.
Human PAcP has a long history of serving as a tumor marker for prostate cancer due to its prostatespeci®c manner of expression (Solin et al., 1990; Zelivianski et al., 1998) . Since the expression of PAcP can be regulated by androgens, this gene has also served as a marker for studying the mechanism of androgen action in prostate cells (Lin et al., 1993) . Recent results demonstrate that the cellular form of PAcP functions as a neutral protein tyrosine phosphatase (PTP) (Lin and Clinton, 1988; Zhang et al., 2001) , and is involved in cell growth regulation by dephosphorylating c-ErbB-2 Meng and Lin, 1998) . Although the DNA sequence of PAcP promoter has been reported (Banas et al., 1994; Sharief and Li, 1994; Virkkunen et al., 1994) , no information is yet available on the molecular mechanism of its cellspeci®c expression in human prostate epithelia. The dierential expression of a desired product in the target tissue is central to the concept of gene therapy. One strategy is to use a tissue-speci®c promoter to express therapeutic genes (Nettelbeck et al., 2000) . Therefore, it is important to unravel the mechanism of tissue-speci®c transcriptional regulation of the PAcP gene for both molecular research and clinical applications.
To gain insight into the regulation of PAcP expression in dierentiated prostate epithelia, we cloned and characterized its promoter region approximately 3 kb upstream from the start codon. A series of constructs containing truncated promoter sequences and the CAT reporter gene have been evaluated for transcription ± promoting activity. We also investigated the functional activity of PAcP promoter in human prostatic cells in comparison with nonprostatic cells.
Results

Positive and negative cis-acting elements of the 5'-flanking sequence PAcP promoter
To analyse the functional domain of PAcP promoter, a series of truncated 5'-flanking PAcP genomic DNA fragments were ligated in front of the CAT reporter in the pCAT-Basic vector (Figure 1 ). Constructs beginning at 72899, 72583, 71668, 71356, 71305, 71258, 7779 and 7205 bp relative to the transcription start site were designated as p2899, p2583, p1668, p1356, p1305, p1258, p779 and p205, respectively. The downstream boundary of each construct was located at +87 bp relative to the starting site of transcription. Three plasmids, each with a deleted region from 7779 to +66 (p2899DI), 71668 to 71258 (p2899DII), or 72583 to 71350 bp (p2899DIII), were also constructed.
The promoter activity was deduced from the quantitation of CAT activity in transiently transfected PC-3 and DU 145 cells. Both cell lines did not express the endogenous PAcP (Garcia-Arenas et al., 1995; , but allowed the expression of the CAT gene driven by the PAcP promoter. The plasmid p2899DI, with a deletion of the basic promoter sequence, showed only the background activity and thus was used as the negative control (Figure 1) . Results of preliminary studies showed that the CAT activity in PC-3 cells transfected with p205 and p779 was approximately the same (data not shown). Thus, the activity of p779 was arbitrarily assigned as 1.0, and used as the reference for normalizing activities of other constructs. Interestingly, p2899 exhibited a similar activity to p779 (Figure 1 ). Deletions in the 5'-flanking sequence of 3 kb promoter DNA had an eect ranging from marginal to enhanced on the CAT activity (Figure 1 ), indicating that both positive and negative cis-elements are involved in the regulation of the PAcP gene expression. The overall quantitative pattern was very similar in PC-3 and DU 145 cells, although PC-3 cells had an overall higher activity than DU 145 cells (Figure 1 ). The CAT activity of p1258 was approximately 10 times that of p779 in PC-3 cells, and six times that of p779 in DU 145 cells. Nevertheless, the CAT activity of p1668 was approximately one-fourth of that of p1258 in DU 145 cells and one-®fth in PC-3 cells. The data thus clearly showed that the region between 7779 and 71258 is required for a high level of expression in prostate cancer cells, while the region of 71668/71356 has a negative regulatory eect (Figure 1 ).
Functional activity of region 72899 to 72583
To characterize the putative regulatory element located in the region between 72899 and 72583, we constructed a CAT plasmid, p2899DIII, in which the DNA fragment between positions 72583 and 71305 was deleted (Figure 1 ). The CAT activity of this construct was less than one-®fth that of p1258 in DU 145 and PC-3 cells (Figure 1 ). The deletion of the sequence from 71668 to 71258, p2899DII, resulted in a similar low level of CAT activity in the reporter plasmid (Figure 1) .
To further examine whether the isolated 316 bp sequence from 72899 to 72583 of the PAcP gene indeed possesses negative regulatory activity, the CAT activity of a reporter plasmid driven by an SV40 promoter containing this sequence was analysed. The CAT-reporter constructs harboring this 316 bp fragment of the PAcP gene in the sense or antisense orientations were transfected into PC-3 and HeLa cells. Results of transfection experiments revealed a decrease of SV40 promoter activity in both PC-3 and HeLa cells (Figure 2a ). In PC-3 cells, the 316 bp DNA fragment at sense and antisense orientations reduced the SV40 promoter activity by 60 and 30%, respectively ( Figure 2a ). An approximately 10% greater inhibition was seen in HeLa cells than in PC-3 cells, indicating that the negative activity of this 316 bp DNA fragment is orientation-independent and lacks tissue speci®city.
Transcriptional activation of a heterologous promoter by the PAcP enhancer element
To determine whether the 577 bp sequence from 71356 to 7779 in the PAcP 5'-flanking region can confer the transcriptional activation of a heterologous promoter, this sequence was cloned in front of an SV40 promoter linked to the CAT reporter gene. When this plasmid was transfected into PC-3, DU 145, and HeLa cells, the CAT activity was elevated in PC-3 and DU 145 but not in HeLa cells. The induction of the SV40 promoter activity was increased about twofold, compared with increases in induction of the cognate promoter of approximately 12-fold in PC-3 cells and sixfold in DU 145 cells (Figure 2b ). Thus the data indicated that this region can confer the cell-speci®c transcriptional activation of a heterologous promoter, although the degree of enhancement is much lower than that of the cognate promoter.
Cell-specific expression of the PAcP gene
The PAcP protein is recognized as one of the most useful biomarkers for malignant diseases (Chu and Lin, 1998) . No PAcP expression is detected in tissues other than prostate (Solin et al., 1990; Zelivianski et al., 1998) . It is therefore important to determine if the positive cis-regulatory element described above retains a high level of the cell speci®city for the characteristic of the PAcP gene.
A variety of cell lines including WI-38 human lung diploid cells, A-431 human epidermoid carcinoma cells, and HeLa human cervix epitheloid carcinoma cells were transfected with dierent reporter constructs. Transient transfection experiments were performed as described above for prostate cancer cells by mixing reporter DNAs with the internal control plasmid pSV-b-galactosidase. As shown in Figure 3 , neither p1258 nor p1356 could express the CAT activity by more than 50% of the reference plasmid p779. In comparison, in PC-3 and DU 145 cells, both p1258 and p1356 could drive the expression of CAT gene to levels approximately 6 ± 10 times that of p779 ( Figure 1 ).
The promoter activity was further quanti®ed by normalizing the CAT activity to microgram of cellular proteins to determine the speci®c activity of expression. The b-galactosidase-speci®c activity was also calculated to demonstrate the transfection eciency in those cells. As shown in Figure 4a , transfection with p779 produced a similar low level of CAT speci®c activity in all three types of cells, with HeLa cells having the lowest speci®c activity. Transfection with p1258 resulted in a more than sevenfold increase in CATspeci®c activity in both PC-3 and DU 145 prostate cancer cells. However, in HeLa cells, p1258 produced only about a twofold increase in the CAT-speci®c activity over p779 ( Figure 4a ). Similarly, transfection of p779 and p1258 in A-431 and WI-38 cells produced only the same low level of CAT-speci®c activity as in HeLa cells (data not shown and Figure 3 ). Signi®-cantly, all cells expressed a similar level of bgalactosidase-speci®c activity (data not shown), indicating a similar transfection eciency. The data may also indicate cell-speci®c activation by 71258/7779 segment in prostate cancer cells. The cell-speci®c expression of PAcP promoter was further investigated utilizing¯uorescence microscopy. PC-3 and HeLa cells were transiently cotransfected with plasmids containing GFP and RFP under the control of PAcP and CMV promoters, respectively. In PC-3 cells, CMV ± RFP and PAcP ± GFP constructs showed similar levels of¯uorescence intensity ( Figure  4b ). However, under the same condition in HeLa cells, much lower¯uorescence intensity was seen for PAcP ± GFP than for CMV ± RFP construct, indicating that the PAcP promoter can drive only a low level of expression in HeLa cells (Figure 4b ). Taken together, the results indicate that the p1356 PAcP enhancer/ promoter sequence may retain the characteristic of the cell-speci®c expression.
Expression of PAcP ± GFP construct in mouse prostate
To examine further the cell-speci®c expression of p1356, the expression of GFP in mouse prostate and skeletal muscle was studied on day 6 after the direct injection of p1356 ± GFP plasmid. The expression of GFP was compared in frozen sections of mouse prostate and muscle, and the phase contrast and uorescence patterns are shown in Figure 5 . Interestingly, the¯uorescence seen in prostate tissue was distributed throughout most of the prostate gland, with a high level of expression in epithelial cells, while a low level of¯uorescence was seen in localized portions of the muscle ( Figure 5 ). The control sample injected with pEGFP lacking the promoter did not show anȳ uorescence (data not shown). The data indicate that the p1356 PAcP enhancer/promoter fragment can drive a high level of expression in prostate epithelial cells but not muscle cells in an intact animal.
Discussion
Although the PAcP gene has been cloned for many years, little information is available about the cisregulatory elements that control its expression. Likewise, little is known about the transcriptional factors involved in regulating the expression of this gene (Shan et al., 1997; Zelivianski et al., 2000) . In this study, we have characterized the promoter of the PAcP gene and identi®ed putative elements that may account for the conditional expression of PAcP gene in prostate cells.
Several lines of evidence support the notion that the cellular form of PAcP functions as a neutral PTP and is involved in growth regulation of dierentiated prostate epithelia (Chu and Lin, 1998; Lin and Clinton, 1988; Lin et al., 1998 Lin et al., , 2001 Meng and Lin, 1998; Zhang et al., 2001) . Interestingly, the expression of PAcP is decreased or suppressed in prostate cancer cells, correlating with a rapid growth rate as well as the androgen-independent growth (Chu and Lin and Clinton, 1988; Lin et al., 1998 Lin et al., , 2001 ). The molecular mechanism of this phenomenon requires further studies. Compared with non-cancerous prostate cells, the androgen-sensitive human prostate cancer LNCaP cells express low levels of PAcP and PSA, two major prostate-speci®c proteins, and are thus suitable for studying the transcriptional regulation of the respective gene. However, the disadvantages of utilizing these cells for in vitro study include the low transfection eciency, a slow growth rate, and a potential complexity caused by the endogenous gene expression (Ruokonen et al., 1996; Zelivianski et al., 1998) . Another widely utilized human prostate cancer cell line, PC-3, also expresses a functional AR, although its level is much lower than that in LNCaP cells and the cell growth does not respond to androgens (GarciaArenas et al., 1995; Lin et al., 1998) . In this cell line, Southern blot analyses demonstrate that the PAcP gene is apparently normal (Garcia-Arenas et al., 1995), while there is no detectable level of PAcP mRNA by Northern blot analyses and RT ± PCR (Garcia-Arenas et al., 1995; Solin et al., 1990 ). An elevated expression of functional AR by an AR cDNA expression vector in PC-3 cells cannot induce the expression of PAcP in these cells (Garcia-Arenas et al., 1995) . Further investigations of regulation of PAcP expression are needed, since cellular PAcP may play a critical role in regulating prostate cell proliferation and malignancy .
Previous studies using Northern blot analyses and nuclear run-o assays have demonstrated the prostatespeci®c expression of the PAcP gene (Solin et al., 1990; Zelivianski et al., 1998) . Sequence analyses reveal that the promoter DNA within 3 kb upstream of the coding region lacks the canonical TATA box and the GC box (Banas et al., 1994; Virkkunen et al., 1994) . The regulatory proteins and factors that are responsible for the prostate-speci®c expression of the PAcP gene remain to be identi®ed. It has been shown that the 1.4 kb (71356 to +87) promoter DNA sequence exerts an inverse correlation with the growth of LNCaP cells (Zelivianski et al., 1998) . However, the identity of the cis-element that is involved in this phenomenon requires further determination. In this study, we have carried out a systematic deletion on the 3-kb of 5'-flanking DNA of PAcP gene to further our understanding of the mechanism of regulation of the human PAcP gene promoter. Our initial studies show that the deletion between 73kb and 71.4 kb signi®cantly increases the promoter activity in prostate cancer cell lines (PC-3 and DU 145). Our data further indicate that the activity of the PAcP promoter is controlled by at least one positive and two negative cisacting elements at the transcriptional level (Figure 1) . Thus, the expression of PAcP gene is regulated by complex mechanisms.
Results of this study clearly show that the sequence within 779 bp of the PAcP gene promoter can drive the transcription activity at a low level in dierent cell types. The similar activity of reporter gene driven by the PAcP basic promoter construct in all cells indicates that the PAcP basic promoter does not require tissuespeci®c factors for transactivating its activity. Interestingly, the inclusion of 71258/7779 (or 71356/7779) region enhances the activity of PAcP basic promoter in prostate but not in non-prostate cells (Figures 1, 3) . The increase of PAcP promoter activity shown by CAT assays in prostate cells correlates with observations after the cotransfection of green and red¯uorescent protein encoding plasmids into PC-3 and HeLa cells (Figure 4b ). Prostate-speci®c DNA-protein complexes are probably responsible for mediating this cell-speci®c expression. The lack of enhanced expression of the Microscopy of CMV ± RFP and PAcP ± GFP constructs in prostate and non-prostate cells. PC-3 and HeLa cells were cotransfected with an equal amount of CMV ± RFP (pDsRed1 ± 1N) and PAcP ± GFP (p1356 ± GFP), and images were taken using appropriate ®lter sets for GFP and RFP, respectively element is involved in regulating tissue speci®city of PAcP expression. The notion that this 479-bp segment of 71256/7779 in the PAcP promoter is a true enhancer is supported further by its ability to increase the transcription activity of a heterologous promoter (Figure 2b ). Interestingly, although this segment could enhance the activity of SV40 promoter in prostate cells, the degree of activation in that construct is much lower than that of PAcP promoter/enhancer (Figure 2b ). It is possible that 7779/+87 region contains sequences required for further activation of PAcP promoter, and the actual enhancer region might extend towards the transcription start site. Detailed analyses of PAcP enhancer and promoter regions will reveal the localization of cis-element(s) governing its tissue-speci®c expression. We have also performed initial biochemical characterizations of the 316 bp of 72899/72583 negative cis-regulatory element. Results reveal that this DNA fragment contains an inhibitory activity in both PC-3 and HeLa cells in an orientation-independent manner (Figure 2a ). Thus, the high level of cell-speci®c expression of the PAcP gene is apparently governed by the positive element but not by this negative element. Hormone-refractory prostate cancer is one of the most detrimental diseases aecting men in the United States. In recent years, gene therapy for treating advanced neoplasm has been proposed. Because the prostate is a non-essential organ, the treatment can be targeted with a tissue-speci®c rather than a tumorspeci®c promoter. Among the gene products speci®-cally expressed by human prostate, the transcriptional regulation of the PSA gene has been widely studied (Cleutjens et al., 1996 (Cleutjens et al., , 1997 Gotoh et al., 1998; Riegman et al., 1991) . However, most of the studies have focused primarily on androgen regulation of the PSA promoter, since its expression is tightly regulated by androgens through the action of the AR. In fact, the majority of patients with advanced, hormonerefractory prostate cancer are under androgen deprivation therapy, which may compromise the activation of the PSA promoter. Thus, androgen inducibility of PSA promoter is a serious obstacle to utilizing that promoter in targeting patients during androgen ablation prostate cancer therapy.
Nuclear run-o assays demonstrate that PAcP expression can be, at least in part, regulated by androgens. Results of further experiments, however, have shown that the regulation of PAcP expression is not androgen dependent, unlike PSA expression (Lin et al., 1993; Zelivianski et al., 1998) . For example, in the steroid-reduced condition, the activity of PAcP promoter is elevated (Zelivianski et al., 1998 (Zelivianski et al., , 2000 . In these studies, we have utilized two androgen-independent prostate cancer cell lines, PC-3 and DU 145, to analyse the functional activity of the PAcP promoter. Transfection experiments show that the PAcP promoter is highly active in those cells in the absence of AR co-transfection or with the addition of androgens. These results strongly indicate that the cell type-speci®c promoter activity of the PAcP gene is regulated in an androgen-independent, responsive manner. Moreover, the cis-regulatory elements that are required for the high level of cell-speci®c promoter activity are likely to be contained within the 1.4-kb promoter fragment. However, these experiments do not exclude the possibility that additional distal regulatory elements could drive an even higher level of the cell-speci®c expression of PAcP in vivo.
Although the naked DNA gives virtually no transfection to cells in vitro, it gives surprisingly ecient gene transfer following in vivo local injection in several tissues, notably muscle (Wol et al., 1992) and skin (Hengge et al., 1995) . Expression of reporter genes in skeletal muscle, heart, and tongue has been shown for the murine creatine kinase promoter (Johnson et al., 1989) , a-cardiac myosin heavy chain (Kitsis et al., 1991) , and modi®ed cytomegalovirus promoter Prigozy et al., 1993; Roman et al., 1992) . The direct injection of plasmid DNA containing a reporter gene driven by the PAcP promoter/enhancer into an intact animal provides a system for studying the regulation of prostate-speci®c expression that can not be modeled in a cell culture. For the ®rst time our results clearly demonstrate that the prostate gland can be transfected in vivo by direct injection of plasmid DNA. Furthermore, we show that the directly injected plasmid DNA containing PAcP promoter/enhancer has a greater expression level in prostate than in skeletal muscle ( Figure 5) . A similar pattern with low level of¯uorescence is observed after injection of p1356 ± GFP into the tongue (data not shown). However, these experiments do not exclude the possibility that the dierential expression of GFP protein between prostate and muscle cells is due in part to the high level of bare DNA uptake by prostate. Further experiments utilizing transgenic animals will provide the answer to whether the cloned 1.4 kb PAcP promoter is sucient to determine prostate-speci®c expression in an intact organism.
In summary, we have cloned a 3-kb promoter DNA of human PAcP gene and have begun to identify regulatory regions that control PAcP gene expression. In this communication, we observe that the obtained promoter apparently exhibits the prostate cell-speci®c activity. Deletion analyses have identi®ed a 479-bp DNA segment that is required for a high level of promoter activity. To the best of our knowledge, this is the ®rst report that clearly demonstrates the cellspeci®c activity of the PAcP gene in cell culture and intact animals. Since no prostate-speci®c transcription factor has been identi®ed, further studies by detailed analyses of the enhancer and promoter region and the corresponding nuclear factors may reveal the molecular mechanism of the cell-speci®c expression of PAcP. Furthermore, understanding the mechanism of its cell-speci®c expression may facilitate the use of appropriate DNA elements in clinical applications. In addition, our results clearly demonstrate that the prostate gland is an excellent target organ for direct gene transfer to examine transcription regulation of prostate-speci®c genes.
Materials and methods
Materials
Cell culture medium, fetal bovine serum (FBS), gentamicin, glutamine, Opti-MEM medium, and LipofectAMINE PLUS reagent were obtained from Life Technologies, Inc. The MasterAmp PCR Optimization kit was from Epicentre Technologies Corp. The Zero Blunt PCR cloning kit and pCR-Blunt vector were obtained from Invitrogen Corp. pCAT-Basic, pCAT-Promoter, pCAT3-Promoter, pSV-bgalactosidase vectors, b-galactosidase, and CAT assay kits were purchased from Promega Corp. pDsRed1-N1 and pEGFP-1 were obtained from Clontech Lab, Inc. DNA manipulations of plasmids were performed by conventional molecular biology techniques (Sambrook et al., 1989) .
Cell culture
DU 145 and PC-3 human prostate cancer cells were routinely maintained in RPMI-1640 medium supplemented with 5% FBS, 1% glutamine, and 0.5% gentamicin. WI-38 human lung diploid cells, A-431 human epidermoid carcinoma cells, and HeLa human cervic epitheloid carcinoma cells were grown in DMEM medium supplemented with 10% FBS, 1% glutamine, and 0.5% gentamicin.
PAcP genomic clone
The p16221 genomic DNA clone containing the PAcP promoter region was obtained from the BAC human genomic DNA library (Genome Systems, Inc.). Southern blot analyses were performed to con®rm the presence of PAcP genomic sequences (data not shown).
Cloning of the PAcP promoter
The promoter fragment of PAcP gene between 72899 and +87 was obtained by PCR ampli®cation using the p16221 clone as the template. The PCR reaction was conducted in a volume of 100 ml in the presence of Pfu DNA polymerase (Stratagene), and Buer F from the MasterAmp TM PCR Optimization kit utilizing a Perkin ± Elmer GeneAmp PCR System 2400 (Perkin ± Elmer). Two oligonucleotide primers (Virkkunen et al., 1994) were utilized: 5'-AAA GTT CAA GGT GCC ACA G-3' and 5'-ACT TCG GTC TAG CCA GAA AAA-3'. The PCR mixture was ®rst denatured by heating at 958C for 5 min. The ampli®cation was performed for 30 cycles using the following conditions: 30 s at 948C, 1 min at 59.68C, and 1 min 30 s at 728C. A DNA fragment of *3 kb was obtained and cloned into the pCR-Blunt vector.
Nucleotide sequence determination
The nucleotide sequence of the entire 3 kb was determined in both directions using a cycle sequencing kit fmol 1 DNA (Promega, USA) based on the dideoxy-chain-termination method. Sequencing reactions were also conducted with the Dye terminator cycle sequencing system, and were analysed at the Sequencing Core Facility of the University of Nebraska Medical Center. Sequencing analyses were performed three times in two clones using both DNA strands.
Construction of reporter plasmids
To analyse the active promoter region of the human PAcP gene, a series of reporter plasmid constructs were made using Oncogene Characterization of human PAcP promoter S Zelivianski et al the backbone of the pCATBasic vector. To analyse the promoter activity, a HindIII/XbaI fragment of the PAcP promoter from the pCR ± Blunt vector was cloned into the pCATBasic plasmid. The constructed plasmid, p2899, contained an approximately 3 kb promoter DNA fragment of the PAcP gene covering the region from 72899 to +87. The plasmids p1668, p1305, and p1258 containing the fragments of promoter DNA from 71668 to +87, from 71305 to +87, and from 71258 to +87, respectively, were obtained from p2899 by digestion with EcoNI, PpuMI, or A¯II, followed by treatment with Mung Bean Nuclease (New England Biolabs), and then were religated. The promoter DNA 72583/+87 in plasmid p2583 was obtained from plasmid p2899 by digestion with KpnI, followed by treatment with Mung Bean Nuclease and religation. The plasmid p779, containing a fragment 7779/+87, was subcloned from p2899 by HindIII and HincII digestions, Mung Bean Nuclease treatment, and the religation. The p1356 plasmid was obtained as described previously (Zelivianski et al., 1998) . The promoter DNA in plasmid p205 (7205/+87) was obtained by PCR using two oligonucleotide primers 5'-TAA GCT TTG GGG AAA ACT GTG ATC TCT CT-3' and 5'-CTT CGC TGC AGC CAG AAA AAA AGC AGC A-3' containing sites for HindIII and PstI restriction enzymes, respectively. Ampli®cation was performed for 30 cycles under the following conditions: 1 min at 948C, 1 min 598C, 30 s at 728C. The DNA fragment was sequenced and cloned into the pCAT-Basic vector using HindIII and PstI restriction sites.
The p2899DI plasmid containing the promoter DNA from 72899 to 7779 was obtained by deleting the region between 7779 and +87 from p2899 by digestion with HincII and XbaI restriction enzymes, and religation after overhead removal by treatment with Mung Bean Nuclease. The reporter constructs containing the promoter DNA with a deletion region of 71668/71258 (p2899DII) and 72583/ 71305 (p2899DIII) were obtained by digestion p2899 with EcoNI/A¯II, and KpnI/PpuMI restriction enzymes, respectively, followed by overhead removal by Mung Bean Nuclease and religation.
To clone the PAcP repressor in front of a heterologous SV40 promoter, the KpnI fragment derived from the pCR ± Blunt plasmid encompassing a 3-kb PAcP promoter was inserted at the KpnI site of the pCAT3 ± Promoter plasmid. The pSVPAcPEn plasmid containing the PAcP 577 bp enhancer in front of the SV40 promoter was obtained by cloning a HindIII/HincII fragment from the p1356 plasmid at the corresponding sites in the pCAT ± Promoter vector.
The p1356 ± GFP plasmid containing the GFP gene under the control of a 1356 bp promoter fragment from the PAcP gene was obtained by subcloning the HindIII/PstI promoter fragment from p1356 at the corresponding site in the pEGFP-1 reporter vector.
Transfection and reporter assays
For transient transfection experiments, cells were routinely plated at a density of 2.5610 5 cells per well in a 6-well plate in RPMI 1640 medium containing 5% FBS for PC-3 and DU 145 cells, or in DMEM supplemented with 10% FBS for HeLa, A-431, and WI-38 cells, 48 h before transfection. The adherent cells were transiently transfected, using 6 ml cationic lipid reagent LipofectAMINE PLUS TM (Life Technology) with 1 mg of plasmid DNA for PAcP promoter/CAT reporter gene constructs in the serum-free Opti ± MEM medium. The second plasmid, pSV-b-galactosidase, was co-transfected at a ratio of 1 : 10 to the promoter/reporter gene construct, serving as an internal control. After 4 h of incubation, an equal amount of medium containing 10% FBS was added followed by incubation for an additional 2 h. Cells were then fed with the fresh medium supplemented with 5% FBS. Forty-eight hours after transfection, cells were washed twice with the PBS, scraped, and lysed in 16 reporter lysis buer (Promega) for CAT and b-galactosidase assays. The protein concentration of cell extracts was measured by Bradford's method (Bradford, 1976) using the Bio-Rad protein assay kit (BioRad Laboratories) with bovine serum albumin as a standard.
Quantitative CAT assays were performed with the same amount of total cell lysate proteins in a reaction volume of 125 ml in the presence of 14 C-chloramphenicol (Amersham Life Science, Inc.) as described in the Promega CAT-assay manual accompanying the assay kit. Samples were incubated overnight, followed by a single extraction with 300 ml xylene. An aliquot of 250 ml organic phase was transferred to a scintillation vial containing 2 ml EcoLume TM scintillation uid (ICN Corp.) and counted with a Beckman LS 1801 scintillation counter. All experiments were repeated at least three times in triplicates.
b-Galactosidase assay
Cultured cells were co-transfected with a pSV-b-galactosidase vector containing the b-galactosidase gene driven by a SV40 promoter as described above. Quantitative b-galactosidase assays were performed with the same amount of total cell lysate proteins in a reaction volume of 200 ml, as described in the Promega CAT-assay manual accompanying the assay kit. Brie¯y, cell lysate proteins were incubated in 100 mM sodium phosphate buer (pH 7.3) containing 50 mM b-mercaptoethanol, 1 mM MgCl 2 , and 0.66 mM o-nitrophenyl-b-D-galactopyronoside at 378C. The optical density was measured at 420 nm.
Fluorescence microscopy
PC-3 and HeLa cells were transiently cotransfected with p1356 ± GFP and pDsRed1 ± N1 plasmids as described above. Three days after transfection, cells were visualized with a Nikon Eclipse TE300 microscope using ®lter sets which discriminate between GFP and RFP¯uorescence. Images were captured with both ®lter sets under identical conditions.
Animal experiments
Male mice 6 ± 8 weeks of age (Harlan Sprague Dawley) were used for intraprostate and intramuscular injections of plasmid DNA. Mice were anesthetized, and then an aliquot of 50 ml of Trypan blue solution containing pEGFP1356 plasmid at a concentration of 0.5 mg/ml was injected into the dorsal lobe of mouse prostate or hamstring muscle. After 6 days, mice were sacri®ced, and their prostate and hamstring muscles were removed and immobilized via snap freezing. Immobilized samples from experimental and control animals were sectioned by a cryomicrotome. Tissue sections were ®xed for 2 min in 7208C methanol and examined without pretreatment to record the expression of GFP¯uorescence. 
